Iulian-Laurentiu Buican
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iulian-Laurentiu Buican has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alina-Catalina Buican-Chirea
U.M.F. Doctoral School Craiova, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
1 shared publication Andreea Mihai
Doctoral School, University of Medicine and Pharmacy of Craiova, Romania. Leamna Clinical Pulmonology Hospital, Romania, Craiova, Romania
1 shared publication- Costin Teodor Streba
Pneumology Department, University of Medicine and Pharmacy, 200349 Craiova, Romania
1 shared publication Costin-Teodor Streba
Leamna Clinical Pulmonology Hospital, Romania. Department of Pulmonology, University of Medicine and Pharmacy of Craiova, Romania, Craiova, Romania
1 shared publicationCristina Călărașu
Leamna Clinical Pulmonology Hospital, Romania. Department of Pulmonology, University of Medicine and Pharmacy of Craiova, Romania, Craiova, Romania
1 shared publication- Mădălina Iuliana Mușat
Experimental Research Center for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, 2 Petru Rareş Street, 200349 Craiova, Romania
1 shared publication
Latest Publications
- Open Access
- 18 September 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (18) , 2344
Depression and Anxiety as Comorbidities in Chronic Obstructive Pulmonary Disease: A Comprehensive Narrative Review
Background: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent, progressive condition often associated with psychiatric comorbidities such as depression and anxiety, which negatively affect disease progression, treatment adherence, and quality of life. Methods: A narrative review was conducted by searching PubMed and Google Scholar for English-language publications from January 2015 to July 2025. This type of review was selected to allow for a broad and integrative analysis of the current evidence on the association between COPD and psychiatric comorbidities, particularly depression and anxiety. To increase comprehensiveness, the reference lists of the included articles and systematic reviews were manually screened, and data extraction and evaluation were conducted independently by two reviewers. Results: Reported prevalence rates vary widely in COPD patients with depression ranging from 10 to 57% and anxiety from 7 to 50%, largely due to differences in patient populations, diagnostic tools, and disease severity. Identified risk factors include female gender, social isolation, smoking, low BMI, comorbidities, and systemic inflammation. These comorbidities are associated with increased exacerbations, higher hospitalization rates, and poorer clinical outcomes. While inhaled therapies may have limited impact on psychiatric symptoms, antidepressants must be used cautiously. Non-pharmacological interventions, including pulmonary rehabilitation, cognitive-behavioral therapy, physical activity, and social support, demonstrate clear benefits. Conclusions: Effective management of COPD requires integrated approaches that address both pulmonary and psychiatric components. Tailored interventions can improve clinical outcomes and quality of life. This review explores the bidirectional relationship between COPD and psychiatric disorders, aiming to highlight risk factors, diagnostic tools, and both pharmacological and non-pharmacological treatment strategies.
- 18 September 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (18) , 2344
Open AccessDepression and Anxiety as Comorbidities in Chronic Obstructive Pulmonary Disease: A Comprehensive Narrative Review
Background: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent, progressive condition often associated with psychiatric comorbidities such as depression and anxiety, which negatively affect disease progression, treatment adherence, and quality of life. Methods: A narrative review was conducted by searching PubMed and Google Scholar for English-language publications from January 2015 to July 2025. This type of review was selected to allow for a broad and integrative analysis of the current evidence on the association between COPD and psychiatric comorbidities, particularly depression and anxiety. To increase comprehensiveness, the reference lists of the included articles and systematic reviews were manually screened, and data extraction and evaluation were conducted independently by two reviewers. Results: Reported prevalence rates vary widely in COPD patients with depression ranging from 10 to 57% and anxiety from 7 to 50%, largely due to differences in patient populations, diagnostic tools, and disease severity. Identified risk factors include female gender, social isolation, smoking, low BMI, comorbidities, and systemic inflammation. These comorbidities are associated with increased exacerbations, higher hospitalization rates, and poorer clinical outcomes. While inhaled therapies may have limited impact on psychiatric symptoms, antidepressants must be used cautiously. Non-pharmacological interventions, including pulmonary rehabilitation, cognitive-behavioral therapy, physical activity, and social support, demonstrate clear benefits. Conclusions: Effective management of COPD requires integrated approaches that address both pulmonary and psychiatric components. Tailored interventions can improve clinical outcomes and quality of life. This review explores the bidirectional relationship between COPD and psychiatric disorders, aiming to highlight risk factors, diagnostic tools, and both pharmacological and non-pharmacological treatment strategies.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA2406
A pilot study of cognitive disorders, depression and anxiety in obstructive lung disease
Introduction: The association of cognition, anxiety and depression with respiratory conditions, are nowadays of key interest in research. Understanding the correlation between the psychiatric symptoms and lung diseases will improve the quality of life for patients. Aims and Objectives: The study aims to establish possible links between psychiatric pathologies and pulmonary obstructive diseases. Methods: After obtaining ethical approval, we enrolled 52 subjects (20-86 years old) whom expressed written consent, with a history of obstructive lung disease, admitted at Leamna Pulmonology Hospital (October 2022-February 2023). We used the Mini Mental State Examination, Montreal Cognitive Assessment, Hamilton Anxiety-Depression Scale to evaluate cognitive, depression and anxiety levels. Results: We found 19 (36.5%) with a history asthma (6 had severe asthma) and 33 (63.5%) with COPD (22 classified GOLD D). Of all, 10 (19.2%) patients had psychiatric history and medication. Patients without knowledge of inhaling medication performed poorly in the psychiatric questionnaires. Even though they had distinctive characteristics, the gravity of the psychiatrics pathology was inversely proportional with level of education and directly proportional with the severity of the respiratory pathology in all patients. Surprisingly, patients with a higher hospitalization rate were less likely to have severe depression or anxiety. Conclusions: The COPD group performed poorly in the applied questioners compared to the Asthma group. Some subjects that had significant changes in psychiatric questioners, were not known with depressive, anxiety or cognitive disorders and needed psychiatric referrals.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA2406
A pilot study of cognitive disorders, depression and anxiety in obstructive lung disease
Introduction: The association of cognition, anxiety and depression with respiratory conditions, are nowadays of key interest in research. Understanding the correlation between the psychiatric symptoms and lung diseases will improve the quality of life for patients. Aims and Objectives: The study aims to establish possible links between psychiatric pathologies and pulmonary obstructive diseases. Methods: After obtaining ethical approval, we enrolled 52 subjects (20-86 years old) whom expressed written consent, with a history of obstructive lung disease, admitted at Leamna Pulmonology Hospital (October 2022-February 2023). We used the Mini Mental State Examination, Montreal Cognitive Assessment, Hamilton Anxiety-Depression Scale to evaluate cognitive, depression and anxiety levels. Results: We found 19 (36.5%) with a history asthma (6 had severe asthma) and 33 (63.5%) with COPD (22 classified GOLD D). Of all, 10 (19.2%) patients had psychiatric history and medication. Patients without knowledge of inhaling medication performed poorly in the psychiatric questionnaires. Even though they had distinctive characteristics, the gravity of the psychiatrics pathology was inversely proportional with level of education and directly proportional with the severity of the respiratory pathology in all patients. Surprisingly, patients with a higher hospitalization rate were less likely to have severe depression or anxiety. Conclusions: The COPD group performed poorly in the applied questioners compared to the Asthma group. Some subjects that had significant changes in psychiatric questioners, were not known with depressive, anxiety or cognitive disorders and needed psychiatric referrals.